Executive SummaryThe stock-market hysteria surrounding EntreMed is only the latest in a series of events we list in which an extraordinary quotation dramatically drives up the stock of a company almost overnight. The hype isn't all bad, it turns out.
You may also be interested in...
Lucky STAR: FDA’s eSTAR Pilot Aims To Make 510(k) Process Smoother With Submission Template For Device Makers
Nine manufacturers will soon have the chance to enroll in a voluntary eSTAR pilot program that the US agency says will make the premarket review process more efficient and consistent. The design and structure of an electronic Submission Template And Resource – or eSTAR – template is similar to templates used by FDA reviewers. An eSTAR won’t change the agency’s statutory or data requirements for sponsors to show substantial equivalence to predicate devices.
W3ll People is expected to add a relatively modest $7m to e.l.f. Beauty’s fiscal 2021 top line, but the brand has “major white space” opportunities, including at Target, e.l.f.’s longest-standing customer. Further, its plant-based product line includes 40 “EWG Verified” products, reflecting expertise e.l.f. is eager to tap.
UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.